Sight Sciences, Inc. · NASDAQ:SGHT
Sight Sciences — Technical Presentation (2023)
15 slides from Sight Sciences's technical presentation, 2023
Slide 1: TearCare Compared to Restasis for Dry Eye Disease: The SAHARA RCT
TearCare® Compared to Restasis for Dry Eye Disease The SAHARA RCT Marc Bloomenstein OD FAAO Thomas Chester OD FAAO Bobby Saenz OD MS FAAO Full Title: Aqueous Retention and Meibum Outflow Restoration (ARMOR™) Procedure Compared to Cyclosporine Ophthalmic Emulsion 0.05% (Restasis®) Eyedrops to Treat t
Slide 2: Disclosure statement
Disclosure statement: • Dr. Bloomenstein: consultant for and honoraria (speaker) from Allergan and Sight Sciences; Clinical Investigator in the SAHARA study • Dr. Chester: grant support, consulting, and speaking for Sight Sciences; Clinical Investigator in the SAHARA study • Dr. Saenz: consultant an
Slide 3: Objectives and Background
Objectives and Background • Dry Eye Disease (DED) may be the most common ocular affliction globally • Meibomian gland dysfunction (MGD) may be the leading cause1 • Treatment approaches include lid hygiene, medications (e.g. liftegrast, cyclosporine), or procedural based options such as TearCare • Te
Slide 4: TearCare
TearCare -~ —_—
Slide 5: SAHARA – Study Schematic
Study Design SAHARA – Study Schematic Eligibility Informed Consent Baseline Measurements Extended (5 months) Inclusion/Exclusion TearCare Retreat Follow-up Baseline & Month 5 TC Through M 24 Month 6 Randomization Primary 1:1 Endpoint Restasis 1. Δ in TBUT X-over to TC (M6) Restasis 2. Δ in OSDI Foll
Slide 6: Baseline demographic and baseline ocular characteristics
Baseline demographic and baseline ocular characteristics All subjects TearCare Restasis Significance Subject-level parameters N=341 N=168 N=173 (p) Age (yr), mean (SD) 56.2 (14.0) 55.5 (14.9) 56.8 (13.1) 0.4057 Gender, n (%) Female 244 (71.6) No 116Baseline (69.0) 128 (74.0) 0.3120 Male 97 (28.4) 52
Slide 7: SAHARA – 1st Primary Effectiveness Endpoint - TBUT
SAHARA – 1st Primary Effectiveness Endpoint - TBUT Endpoint - TBUT Change from Baseline TBUT - Actual TearCare superior to Restasis in TBUT change from baseline at 6 months (P<.0001) **** ** *** ** Means, ± 1 SD All time points, both groups p<.0001 vs. baseline Analysis: Linear mixed effects with ad
Slide 8: SAHARA – 2nd Primary Effectiveness Endpoint - OSDI
SAHARA – 2nd Primary Effectiveness Endpoint - OSDI Endpoint - OSDI Change from Baseline OSDI - Actual TearCare non-inferior to Restasis in OSDI change from baseline at 6 months (P=.9843) Means, ± 1 SD OSDI scale is 0 to 100 Based on the score, the patients' symptoms can be categorized as: All time p
Slide 9: SAHARA – Secondary Endpoints – Signs – Meibomian Gland Outcomes
SAHARA – Secondary Endpoints – Signs – Meibomian Gland Outcomes TearCare superior to Restasis in change from BL at M6 for: • Meibomian gland secretion score (MGSS) (P<0.0001) • Number of glands yielding any liquid (MGYALS) (P<0.0001) • Number of glands yielding clear liquid (MGYCLS) (P<.0008) Meibom
Slide 10: SAHARA – Secondary Endpoints – Corneal & Conjunctival Staining; Schirmer
SAHARA – Secondary Endpoints – Signs – Corneal & Conj Staining; Schirmer TearCare non-inferior to Restasis (Change from BL at M6): • Corneal Staining Score (P=.0820) • Conjunctival Staining Score (P=.1213) • Schirmer Test Score (P=.7910) Corneal Staining Conjunctival Staining Schirmer Test ** * * •
Slide 11: SAHARA – Secondary Endpoints – Symptoms
SAHARA – Secondary Endpoints – Symptoms Symptom Assessment In Dry Eye (SANDE) TearCare non-inferior to Restasis in SANDE change from baseline at 6 months (P=.4222) * All time points, both groups p<.0001 vs. baseline * Eye Dryness Score TearCare non-inferior to Restasis in EDS change from baseline at
Slide 12: SAHARA - Safety
SAHARA - Safety Both treatments were generally safe and well tolerated • 19 adverse events (AE) in each treatment group (11.0%) – 2 in the TearCare group and 8 in the Restasis group were graded as possibly related to study treatment – All graded as mild (n=9) or moderate (n=1) in severity. • Ocular
Slide 13: Conclusions
Conclusions When 2nd generation TearCare technology and procedure was compared to Restasis, TearCare was: • Statistically superior in TBUT and multiple measures of meibomian gland secretion • Non-inferior to Restasis in OSDI, corneal and conjunctival staining, SANDE score, EDS, and STS, providing st
Slide 14: Conclusions
Conclusions • Traditional therapy for DED (typically eyedrops) is reliant on patient adherence for effectiveness but patients with DED often do not adhere to their eyedrops at the specified frequency.2 • In this study as in many clinical trials3, subject adherence to drop therapy was very good (not
Slide 15: EW ORLEANS
WZ) = EW ORLEANS